Dengue vaccine development has made significant strides, but a better understanding of how 18 vaccine-induced immune responses correlate with vaccine efficacy can greatly accelerate development, 19 testing, and deployment as well as ameliorate potential risks and safety concerns. Advances in basic 20 immunology knowledge and techniques have already improved our understanding of cell-mediated 21 immunity of natural dengue virus infection and vaccination. We conclude that the evidence base is 22 adequate to argue for inclusion of assessments of cell-mediated immunity as part of clinical trials of 23 dengue vaccines, although further research to identify useful correlates of protective immunity is 24 needed. 25 26
Introduction 27
The immunological basis of the efficacy of many of the most well-established vaccines is poorly 28 understood, and, where studies to better understand vaccine efficacy have been done, they have almost 29 always relied on tests of pathogen-specific antibodies rather than on measures of cell-mediated 30 immunity (CMI) [1] . Several reasons likely explain this bias; serum is more easily obtained than viable 31 lymphocytes, antibodies can be studied in isolation, and assays of antibody concentration and function 32 are technically more straightforward and reproducible than cellular assays. Fortunately, in many cases 33 detection of antibodies at or above a defined concentration using specific assays has proven to serve as 34 a useful correlate of protective immunity. However, there has been ample evidence in the case of 35 established vaccines that the information provided by assays of antibody responses is often incomplete, 36 and that protective immunity (sometimes only partially protective) was present in some individuals 37 without protective antibody levels. 38 A consultation was organized by the WHO in 2007 to "review the state of the art of dengue CMI 39 and to discuss the potential role of CMI in advancing dengue vaccine candidates towards licensure" [2] . 40
The participants concluded that "precise function of CMI in protection or disease pathology remains ill-41 defined and, at present, there is no evidence to suggest that CMI can be utilized as a correlate of 42 protection." Recent data from dengue vaccine trials has renewed interest in addressing this issue, 43 however. In the pivotal phase III trials of the Sanofi Pasteur chimeric dengue virus (DENV) -yellow fever 44 virus (YFV) vaccine, plaque reduction neutralization titers (PRNT) only weakly correlated with protection, 45 and breakthrough infections occurred in some individuals with high PRNT values [3, 4] . While efforts 46 continue to refine assays of DENV-specific antibodies in order to discriminate effective/protective from 47 ineffective/non-protective antibodies (assuming that this is possible), these findings re-emphasize the 48 need to consider the role of DENV-specific T lymphocyte responses in vaccine efficacy. This review seeks 49 to summarize the current state of knowledge regarding DENV-specific CMI and propose potential 50 contributions of CMI measurements to dengue vaccine development and testing. 51
An appraisal of the literature on DENV-specific T cell responses merits a brief review of current 52 paradigms in T cell biology and relevant technologies. One area highlighted by recent work is the 53 complexity of effector T cell subsets. Extending the paradigm of Th1 versus Th2 responses among CD4 T 54 cells, at least 7 different phenotypes have now been described [5, 6] . Table 1 summarizes key proteins 55 expressed by each subset. Cytokines and other signals produced by antigen-presenting cells during the 56 initial T cell activation (not listed in the table) determine which pathway is taken by an individual T cell 57 through the induction of the transcription factors listed, and this in turn controls the profile of 58 chemokine receptors and cytokines produced. The characteristic cytokines produced by each subset are 59 the major determinant of its role in immunity and also tend to reinforce cell polarization. The profile of 60 chemokine receptors expressed by each cell subset determines that subset's predominant anatomical 61 distribution, such as peripheral versus mucosal versus secondary lymphatic sites, which also contributes 62 to its function in the response to different pathogens. Cytolytic activity, not traditionally considered an 63 important effector function of CD4 T cells, has been increasingly recognized, mainly among cells 64 expressing Th1 cytokines [7] . In contrast, while cytolysis has long been seen as the main function of CD8 65 T cells, there has been a growing recognition of more diverse subsets within this population. CD8 T cell 66 subsets with cytokine profiles similar to several of the CD4 subsets listed in Table 1 have been described,  67 although there is comparably less known about them. Based on studies in mice, T cell polarization has 68 often appeared to be a fixed characteristic of the cell determined during its initial activation. However, 69 studies in humans suggest more plasticity in T cell phenotype [8] . 70
Another area of active research in T cell biology is the developmental relationships between 71 naïve, effector, and memory T cells [9] [10] [11] . This topic entails significant debate, as, unlike the case with B 72 lymphocytes, there are no universally accepted standards for defining a memory T cell; several different 73 schemas have been proposed to define the phenotypes of effector versus memory T cells, but it is clear 74 that these are imperfect. From a functional standpoint, it is recognized that, among antigen-experienced 75 T cells, there is a subset of short-lived effector cells that are destined to undergo apoptosis whereas 76 other cells demonstrate the capacity for long-term persistence and even self-renewal. Within the long-77 lived memory cell population, heterogeneity in function and protein expression led to a distinction of 78 central memory T cells (T CM ) and effector memory T cells (T EM ). Recent data have revealed further 79 complexity, and led to the classification of several additional subsets such as tissue-resident memory T 80 cells (T RM ) and stem memory T cells. Rather than fixed cell fates, however, there is evidence that these 81 phenotypes retain some degree of plasticity. The timing and determinants of the transitions between 82 states are not fully understood, and remain an important area of investigation. Several markers have 83 been clearly identified as strongly associated with a cell's capacity for long-term survival, such as high 84 expression of IL-7R and low expression of KLRG1. 85 86
Assay methods 87
Persisting antibody following vaccination is recognized as the first line of defense against 88 subsequent infection and is regarded as a distinguishing characteristic of an effective vaccine [12] . All 89 currently licensed anti-viral vaccines elicit a robust antibody response that correlates with the level of 90 protection provided by the vaccine [13] . If the same should prove to be true for dengue, then the search 91 for a CMI "correlate of protection" for dengue would be unnecessary. However, dengue is one of several 92 globally important infectious diseases, along with HIV, malaria, and tuberculosis, for which a vaccine is 93
highly desirable yet no validated animal model or correlate of immune protection is known. While 94 empirical testing of candidate vaccines has been successful in the past, the era of molecular biology has 95 led to an explosion of tools and methodologies for creating new vaccine antigens and vector delivery 96 systems. The contribution of CMI, particularly T cells, to a successful dengue vaccine is highly likely 97 whether it be as direct effector cells, provision of help for antibody development or creating a 98 generalized anti-viral environment. Together with the antigenic complexity of candidate dengue 99 vaccines (Table 2) Fortunately, T cell-based immunoassay development has also proceeded at a remarkable rate 103 [14, 15] . A list of assays together with their advantages and disadvantages is presented in Table 3 . 104
Recently the focus of immune-monitoring has been upon assays that provide "minimal manipulation." 105
Relatively high-throughput assays such as ELISPOT and intracellular cytokine staining (ICS), which utilize 106 in vitro stimulation times of less than 24 hours (or no stimulation in the case of direct ex vivo flow 107 cytometry), are the assays of choice as a screening tool. When well qualified, both platforms are 108 quantitative and specific for the antigen. While validation of ELISPOT and ICS assays is not trivial, it is 109 possible, and if a T cell-based correlate of protection for dengue is defined one of these platforms would 110 most likely be the basis of such an assay [16, 17] . The general disadvantage of ELISPOT assays is that 111 some a priori knowledge of the relevant functions is required. IFN- has been used extensively in vaccine 112 development as a marker of vaccine take and as a function that is necessary, but perhaps not sufficient, 113 for protection. ICS expands upon the functional profile of ELISPOT assays, bringing the concept of 114 polyfunctionality of T cells to the fore. Again, some a priori knowledge of the relevant functional profile 115 is required to fully interpret the results of this assay. Furthermore, ELISPOT and ICS assays are best 116 suited for measuring and quantifying the direct effector capacity of T cells (IFN-, TNF, and cytolytic 117 potential), but are significantly less sensitive at measuring T cell helper capacity. Mass cytometry and 118 advanced polychromatic flow cytometry are technologies that permit the analysis of as many as 36 119 parameters simultaneously on a single cell. These parameters may include both phenotypic and 120 functional markers. While these methods will facilitate high-dimensional, quantitative analysis of 121 biomolecules on cell populations at single-cell resolution, their application to dengue research has so far 122 been limited [18, 19] . 123
The most sensitive assays are generally those that involve proliferation of a small number of 124 antigen-specific precursor cells. Dye-dilution based T cell proliferation, when appropriately calibrated, 125
can identify the phenotype of proliferating T cells as well as quantify the precursor frequency [20] . In 126 addition, cytokines associated with helper (e.g., IL-4, IL-5, IL-13, IL-21) or regulatory (e.g., IL-10, TGF-) 127 capacity can be studied in supernatants collected from proliferation assays. This approach does however 128 digress from the minimal manipulation concept, is less reproducible and is prone to in vitro variation 129 artifact. 130
Microfluidics-based technologies have led to the possibility of extensive transcriptional profiling 131 of T cells at the single-cell level and a description of the population dynamics of T cell responses. While 132 better suited to a research-based environment, these methodologies provide a discovery platform that 133 will deliver the best opportunity to uncover a correlate of protection [21, 22] . Ultimately a thorough 134 profiling of the entire "immune space" that is occupied by a dengue vaccine will be required to compare 135 and contrast different vaccine modalities and vaccination strategies [23] . Describing the quality, quantity 136 and durability of immune responses elicited will involve a standardized approach incorporating many of 137 assay procedures listed above and probably new technologies as they become deployable. 138
Should a CMI correlate of protection from dengue infection be identified, a significant effort will 139 be required to qualify and validate assays platforms that will reliably detect and/or measure the 140 correlate or function. As described earlier, validation of ELISpot or ICS format assays has proved 141 possible; however, the further challenge will be applying these assays to meet the needs of the global 142 dengue vaccine research community. The field would benefit from the establishment of centralized 143 laboratory(s) that implement External Quality Assurance (EQA) Programs for overseeing the 144 development of external proficiency testing programs for flow cytometry, ELISpot and other CMI-based assays [24] [25] [26] [27] . EQA programs serve three purposes and are run according to Good Clinical Laboratory 146 Practice (GCLP) guidance: 1) provide a means for laboratories to ensure that the data generated are 147 accurate, timely and clinically relevant; 2) provide assurance to sponsors that the data is reliable and 148 high quality; and 3) ensure the appropriate and accurate use of human specimens obtained from clinical 149 trials. In addition to EQA programs, the establishment of biorepositories of standardized qualified 150 reagents and antigens (e.g. PBMCs, peptide sets, viral isolates) for use in helping laboratories validate 151 assays would be invaluable strongest to the serotype to which the subject had been exposed, but variable degrees of cross-167 reactivity are usually observed to one or more of the other serotypes.
Notwithstanding the confirmation of the above paradigms, the greater understanding of T cell 169 biology and advancements in techniques for analysis of T cell responses described above have provided 170 a more detailed and complex picture, particularly with regard to the different characteristics of the 171 memory T cell response and their potential functions during the recall response to a subsequent DENV 172 infection. Inasmuch as vaccination is intended to induce an immune response that will protect against 173 infection or disease during a subsequent DENV exposure, these findings are highly relevant to evaluating 174 the immunogenicity of different vaccine regimens. However, extrapolating observations from natural 175 DENV infection to current vaccines is confounded by several important differences, as will be discussed 176 further below. At least 10 studies have used HLA-peptide tetramers to analyze DENV-specific T cells either 210 directly ex vivo or after in vitro expansion [36, 38, 42, 47-49, 52, 59, 66, 73] . However, six of these 211 studied the same HLA-A*1101-restricted "GTS" epitope on the NS3 protein; in total, the remaining 4 212 studies investigated 5 other CD8 T cell epitopes and 2 CD4 T cell epitopes. Thus, conclusions based on 213 this body of data still are subject to considerable potential for bias. 214
Contributions from animal models 216
Differences between study populations in host genetics as well as prior DENV exposures 217 continue to complicate the comparison of findings across studies. Given the difficulty in documenting or 218 controlling these factors, there continues to be substantial interest in experimental animal models, 219 particularly small, genetically defined animals such as mice. Several "humanized" mouse models have 220 been studied. In several studies of transgenic mice expressing single HLA alleles, investigators 221 demonstrated recognition of candidate epitopes that were selected for predicted HLA binding; 222 subsequent testing of DENV-immune humans confirmed responses to some but not all of these epitopes 223 through an NIAID-funded reagent repository (www.beiresources.org), but these were not used in most 239 of the published studies. Additionally, there remains a lack of consensus on the optimal criteria for 240 defining epitopes. Immunodominant epitopes-those that induce responses of high magnitude in the 241 majority (often nearly all) of subjects with the appropriate HLA allele-have generally shown similar 242 results across studies, but these represent a minority of the epitopes identified and the generalizability 243 of the observations regarding these epitopes needs to be verified. 244
As mentioned above, the distribution of T cell epitopes across all DENV proteins, albeit with a 245 predominance of epitopes on nonstructural proteins, has been reinforced by the expanded literature. However, this conclusion is based on their approach of HLA class I epitope prediction. It is reasonable to 252 hypothesize that other immunologically important epitopes, especially HLA class II-restricted epitopes, 253 have yet to be defined. Studies have yielded conflicting data on whether the distribution of CD4 T cell 254 epitopes is similar or different from that of CD8 T cell epitopes [48, 57] , with one study reporting that 255 CD4 T cells more often recognized epitopes on structural proteins [57] . 256
The use of single-cell assays such as ELISPOT has complicated the interpretation of serotype-257 cross-reactivity of T cell responses, as these assays do not assess serotype-cross-reactivity at the level of 258 individual cells. This is a particular problem in individuals who have been exposed to more than one 259 DENV serotype, either through sequential exposure or multivalent immunization. Although one study 260 concluded that serotype-specific epitopes could be defined based on sequence conservation alone [78], 261 other experimental data are directly contradictory [36, 37, 41]. Another study described a panel of CD4 262 T cell epitopes predicted to be serotype-specific based on high sequence divergence across serotypes serotypes has been shown to alter the profile of cytokines produced, suggesting that variant epitopes 284 act as altered peptide ligands for some DENV-specific T cells [36, 37] . 285
Comparably less is known regarding effector responses other than Th1/Tc1. Of the few studies 286 that reported data on the production of type 2 cytokines, most reported little or no production of IL-4 287 except one study of very young children (mean age 7.7 months) [ Models of sequential infection with different DENV serotypes postulate that the immune 294 response to secondary infection will differ in several important ways from that to the primary infection: 295 a) the memory T cell response will be induced more rapidly and achieve higher levels, b) the memory 296 response will preferentially activate T cells directed at epitopes that are more highly conserved between 297 the different DENV serotypes, mainly on non-structural proteins, and c) the memory T cell response will 298 have an altered effector profile reflecting differential activation by peptides from the second DENV 299 serotype [83] . Although testing these postulates is highly relevant to understanding both protective and 300 detrimental immune responses in dengue, only a few studies have compared immune responses during 301 or after primary versus secondary DENV infections. Consistent with the predictions, differences have 302 been reported in the expression of some phenotypic markers [71], in the dominant epitopes targeted 303
[78], and in the profile of serotype cross-reactivity [52, 82] . Surprisingly, no significant differences were 304 observed in the kinetics of the response or in the peak T cell frequencies during the acute infection [48, 305 52]. These studies involved only symptomatic DENV infections, however, and the intrinsic incubation 306 period prior to the onset of symptoms could not be determined. Also, the clearance of viremia may be 307 more rapid in secondary infections, as suggested by some data [84] . These significant differences could 308 have masked differences in the kinetics and magnitude of the immune response in primary versus 309 secondary infections. 310 311
Vaccines vs. natural infection 312
With the expanding pipeline of vaccines in clinical testing and the wider availability of the 313 requisite expertise and technology, there has been a growing body of literature describing the T cell 314 response to dengue vaccines. All of the recently published studies have involved candidate live 315 attenuated vaccines. These studies have shown that DENV-specific memory T cells, including 316 polyfunctional Th1/Tc1 cells, are induced within 21 days after vaccination of flavivirus-naïve subjects 317
[56]. In comparison to vaccination with its individual components, vaccination with the tetravalent 318 formulation of the NIH/Butantan vaccine (Table 2 ) preferentially induced T cell responses to peptides 319 from the more conserved non-structural proteins [70] . Interestingly, vaccination with the Sanofi Pasteur 320 chimeric DENV-YFV vaccine induced T cell responses to epitopes on DENV NS3 protein in DENV-immune 321 subjects but not in DENV-naïve subjects, suggesting that the heterologous YFV epitopes could reactivate 322
pre-existing memory CD8 T cells but not antigen-inexperienced T cells [62]. Comparison of the T cell 323
responses induced by the different dengue vaccines listed in Table 2 is not possible, however, because 324 of significant differences in study and assay design. 325 326 Potential contributions of T cell assays to dengue vaccine development 327
The area where assessment of T cell responses to dengue vaccines would clearly have greatest 328 impact is in identifying correlates of vaccine efficacy. A reliable immunological correlate of vaccine-329 induced protective immunity would accelerate vaccine testing in different populations, regimens, or 330 epidemiological contexts. The limitations of current neutralizing antibody assays reinforce the need for a 331 better understanding of correlates of protective immunity, although the poor discriminant ability of 332 neutralizing antibody titers may point either to deficiencies in the assay or to non-antibody protective 333 mechanisms. Human cohort studies and animal experiments have found associations between T cell 334 IFN- production and protective immunity [51, 60, 85, 86], supporting the potential to identify T cell 335 responses associated with protective immunity induced by vaccination. However, the published data are 336 quite limited. Only two studies correlated T cell responses in blood samples collected prior to exposure 337 with clinical outcomes in individual subjects [51, 87] ; both studies relied on the same prospective cohort 338 and the sample sizes were small. Also, given the difficulty in defining individuals who are fully protected 339 from infection, all subjects in these studies experienced DENV infections and comparisons were based 340 on severity of illness (hospitalized dengue versus non-hospitalized dengue in one study and subclinical 341 versus symptomatic infection in the other). Other studies measured T cell responses only during or after 342 DENV infection, a significant confounding factor for any conclusions regarding causality. This concern is 343 somewhat lessened in the case of experimental infection, where protective immunity was associated 344 with early IFN- responses [88] . In light of the limitations of published data, however, it will be essential 345 to validate immunological correlates against clinical endpoints in vaccine trials. 346
It will be important to validate any immunological correlates independently for several different 347 vaccines, because the associations between immunological readouts and vaccine efficacy may or may 348 not be equivalent. In addition to the differences in immune response pathways that might be stimulated 349 by live versus inactivated or subunit vaccines, there are significant differences in antigenic content 350 among the dengue vaccines currently in clinical development (Table 2) . This is most pronounced with 351 regard to the repertoire of flavivirus non-structural (NS) proteins, with some vaccines containing no NS 352 proteins (subunit and inactivated vaccines, although the latter may include some NS1 protein), some 353 containing NS proteins of one flavivirus, either DENV2 or the heterologous YFV, and one containing NS 354 proteins of 3 of 4 DENV serotypes. Since non-structural proteins contain the majority of T cell epitopes, 355
the repertoire of T cell responses induced by each vaccine will likely differ as well, although the resulting 356 immunological profile is difficult to predict at this stage. 357
A second area where measurement of T cell responses could make an important contribution is 358 in evaluating the durability of vaccine-induced protective immunity. This is likely to be of particular 359 importance for dengue vaccines given the evidence that partial immunity increases the risk for more 360 severe illness. Substantial insight has been gained into how the initial activation of T cells contributes to 361 the establishment of both long-lasting T cell and B cell memory, and this process has been successfully 362 manipulated with pharmaceuticals such as rapamycin in experimental models [89, 90] . Licensed 363 vaccines against other diseases differ significantly in the durability of pathogen-specific antibodies and T 364 cells [91]; through comprehensive "systems vaccinology" approaches, early indicators of antibody and T 365 cell responses have been identified for several of these vaccines [92, 93] , although further studies are 366 needed to establish their ability to predict longer-term durability of the response. 367
The single-cell resolution and potential to evaluate multiple T cell effector functions of newer 368 assays offer the capacity to reveal extraordinary detail on the relationships between these responses. 369
This capacity will likely be of special interest in the case of dengue vaccines, given the multivalent nature 370 of dengue vaccines, the need to provide protective immunity against all four DENV serotypes, and the 371 evidence that more severe dengue disease is associated with an inflammatory immune response. Data 372
from several studies showing the induction of polyfunctional T cells by different tetravalent dengue 373 vaccines are encouraging [56, 70, 75]. However, it is unclear whether the degree of 'polyfunctionality' 374 described is optimal; similar frequencies of polyfunctional T cells are seen after natural DENV infection, a 375 setting that does not reflect fully (i.e., tetravalent) protective immunity. Partial immunity to DENV 376 present prior to vaccination, as was seen in the majority of subjects in phase III vaccine trials in endemic 377 areas [3, 4] , could also modify the pattern of T cell effector functions. 378 379
Conclusions and recommendations 380
Although assessments of pathogen-specific T cell responses have not been a priority in most 381 vaccine development efforts, we argue that dengue is a special case and that planning and preparation 382 for such assessments should be given greater emphasis. The example of natural infection illustrates the 383 potential for both positive (protective) and negative (pathological) effects of partial immunity to DENV, 384 and potential concerns for long-term safety will likely remain a major impediment to licensure and 385 widespread uptake of dengue vaccines. The current understanding of T cell responses to DENV indicates 386 the potential for evaluations of T cell responses to accelerate vaccine design and testing by helping to 387 identify correlates of vaccine efficacy and also to reduce the risk to vaccine developers by helping to 388 understand negative outcomes of vaccine trials, should they occur [94] . Implementing analyses of T cell 389 responses in the context of upcoming dengue vaccine trials will present a number of significant logistical 390 challenges (Table 4 ). Based on current knowledge, it is not possible to define the assay or assays that 391 would reliably serve all of the pertinent objectives. 
